Development of immunotoxicity testing strategies for immunomodulatory drugs.
The ICH S8 immunotoxicity testing guideline for human pharmaceuticals was published in 2006 and was intended to provide guidance for assessing the immunotoxicity potential of low-molecular-weight drugs that are not intended to alter the immune system. For drugs intended to modulate the immune system, immunotoxicity testing strategies are generally developed on a case-by-case approach since the targets, intended patient population, and mechanisms of action of the test compound will determine the type of testing needed. Some of the general principles of ICH S8, however, may be applied to immunotoxicity testing strategies for immunomodulatory drugs. A weight-of-evidence approach using factors discussed in ICH S8 in concert with an assessment of the potential value of additional immunotoxicity testing should be considered. For most situations, immunotoxicity studies with immunomodulatory compounds evaluate off-target effects on the immune system and exaggerated pharmacology. The potential use of data from these studies and considerations such as translatability to humans are discussed.
Drug Safety R&D, Pfizer, Inc., Groton, Connecticut 06340, USA. thomas.t.kawabata@pfizer.com
Thomas T
TT
Kawabata
Ellen W
EW
Evans
D004341:Drug Evaluation / Q000379:methods* / Q000592:standards*; D017408:Guidelines as Topic; D006801:Humans; D007155:Immunologic Factors / Q000633:toxicity*
D007155:Immunologic Factors